www.horizonscan.nl gebruikt cookies om het gebruik van de website te analyseren en het gebruiksgemak te verbeteren. Lees meer over
cookies
op www.rijkshuisstijl.nl
Sluiten
You are here:
Horizonscan geneesmiddelen
Medicines
Search the site
Search
Published on
9 January 2018
Compact view
Extended view
Grouped by indication
Grouped by status
Grouped by reason of inclusion in Horizonscan Geneesmiddelen
Grouped by submission date
Grouped by expected registration date
Grouped by manufacturer
Grouped by mechanism of action
Grouped by particularity
Grouped by registration phase
Grouped by domain
Ungrouped
Filters
Sluit
Registration
Show ATMPs only
Show Orphan drugs only
Mechanism of action
Any mechanism of action
Unknown
Alkylating agent
Allergen
Allogeneic modified cell therapy
Amino acid
Anesthetic
Angiogenesis inhibitor
Antiandrogen
Antibiotic
Antibody-drug conjugate
Anticoagulant
Antifungals
Antihistamine
Antioxidant
Antisense oligonucleotide
Autologous modified cell therapy
Bcl-2 inhibitor
BET inhibitor
Calcineurin inhibitor
Cancer vaccine
Cannabinoid
CAR-T therapy
CDK4 / 6 tyrosine kinase inhibitor
CFS1R inhibitor
CGRP-directed antibody
Chelating agent
Coagulant
Combination therapy
Complement inhibitor
Corticosteroid
CTLA-4 antibody
Cytostatic
Disinfectant
Enzyme
Enzyme inhibitor
Enzyme replacement therapy
Gene therapy
GLP-1 receptor agonist
Glucagon analogue
Growth factor
HIV inhibitor
Hormonal therapy
Immunostimulation
Immunosuppression
Insulin preparation
Interferon inhibitor
Interleukin inhibitor
Ion channel blocker
JAK tyrosine kinase inhibitor
LABA / ICS
LABA / LAMA
LABA / LAMA / ICS
LAMA
MEK kinase inhibitor
Neurotoxin
Neurotransmitter
Oncolytic adenovirus
Other
Other, see general comments
PARP inhibitor
PD-1 / PD-L1 inhibitor
Proteasome inhibitor
Protein chaperone
Receptor agonist
Receptor antagonist
Serine / threonine kinase inhibitor
SGLT inhibitor
Small interfering RNA (siRNA)
Sodium channel blocker
Thrombin inhibitor
TNF-alpha inhibitor
Tyrosine kinase inhibitor
Vasodilator
Virus inhibitor
Budgetting framework
Any budgetting framework
Unknown
Extramural (GVS)
Intermural (MSZ)
Particularity
Any particularity
Unknown
New medicine with Priority Medicines (PRIME)
New therapeutical formulation
Reason of inclusion
New medicines
Indication extensions
IND
Biosimilars / generics
BS
G
Download
ALS
Masitinib
Asthma
Benralizumab
Dupilumab
Tiotropium bromide
Tralokinumab
Bacterial infections
Amoxicilline / omeprazol / rifabutin
Cadazolid
Eravacycline
Liposomaal amikacine
Meropenem / vaborbactam
Omadacycline
Ozenoxacine
Recombinant vaccin voor meningokokken groep B
Bladder cancer
Atezolizumab
Durvalumab / Tremelimumab
Pembrolizumab
Ramucirumab
Blood clotting
Andexanet alfa
Betrixaban
Ciraparantag
Vonicog alfa
Bowel diseases
Alicaforsen
Pouchitis
Ulcerative colitis (UC)
Expanded human allogenic mesenchymal adult stem cells extracted from adipose tissue
Lubiprostone
Masitinib
Remestemcel-L
Rifaximin
Tofacitinib
Brain cancer
Brain cancer vaccine
Depatuxizumab mafodotin
Breast cancer
Abemaciclib
Atezolizumab
Fulvestrant
Neratinib
Olaparib
Pembrolizumab
Ribociclib
Breast cancer, advanced metastatic, HR+ and HER2-, in combination with fulvestrant, postmenopausal women and men, 1L en 2L
Breast cancer, advanced metastatic, HR+ and HER2-, in combination with tamoxifen and goserelin or a non-steroidal aromatase inhibitor (NSAI) and goserelin, premenopausal women.
Trastuzumab
Veliparib
Breast cancer; early-stage triple-negative - neoadjuvant therapy with carboplatin
Breast cancer; HER2-negative metastatic or locally advanced unresectable BRCA-associated - first to third-line in combination with carboplatin and paclitaxel.
COPD
Fluticasone furoate / umeclidinium (bromide) / vilanterol (trifenatate)
Glycopyrrolate / formoterol
Mepolizumab
Cardiovascular diseases
Avacopan
Canakinumab
Evolocumab
Prasugrel
Rivaroxaban
Tocilizumab
Colon cancer
Nivolumab
Cystic fibrosis
Tezacaftor / ivacaftor
Dementia
Leuco-methylthioninium
Alzheimer’s disease, mild-to-moderate.
Dementia, behavioural variant frontotemporal.
Diabetes
Dapagliflozine
Ertugliflozin
Ertugliflozin (L-pyroglutamic acid) / metformin (hydrochloride)
Ertugliflozin (L-pyroglutamic acid) / sitagliptin (phosphate monohydrate)
Exenatide
Glibenclamide
Semaglutide
Epilepsy
Vigabatrin
Eye disorders
Adalimumab
Cenegermin
Ciclosporin
Keratoconjunctivitis sicca (or dry eye disease), moderate-to-severe and specifically in patients with atopic keratoconjunctivitis.
Treatment of severe vernal keratoconjunctivitis in children from 4 years of age and adolescents.
Mercaptamine
Pegpleranib
Voretigene neparvovec
Graft versus Host
Ibrutinib
Haemophilia
Damoctocog alfa pegol
Emicizumab
Rurioctocog alfa pegol
Viable T-cells
Head and neck cancer
Afatinib
Durvalumab / Tremelimumab
Pembrolizumab
Headache
Eptinezumab
Erenumab
Galcanezumab
Heart failure
Allogenic immunomodulatory progenitor cells
Autologous stem cells
Ularitide
Valsartan / sacubitril
Hemostasis
Human fibrinogen / Human thrombin
Hormonal disorders
Abaloparatide
Cinacalcet
Enclomifene (citrate)
Pasireotide LAR
Prasterone
Recombinant parathyroid hormone
Infectious diseases other
Benznidazole
Kidney cancer
Atezolizumab
Ipilimumab
Sunitinib
Leukemia
Blinatumomab
Adults with minimal residual disease (MRD) positive B-cell precursor acute lymphoblastic leukaemia (ALL).
Relapsed / Refractory Ph+ Adult Acute Lymphoblastic Leukemia (ALL).
Relapsed / Refractory precursor-B Acute Lymphoblastic Leukemia (ALL) in children.
Bosutinib
Cytarabine / daunorubicin (liposomaal)
Dasatinib
Gemtuzumab ozogamicin
Idelalisib
Inotuzumab ozogamicin
Midostaurin
Nilotinib
Tisagenlecleucel
Venetoclax in combinatie met rituximab
Liver cancer
Nivolumab
Regorafenib
Liver diseases
Obeticholic acid
Lung cancer
Alectinib
Anamorelin
Atezolizumab
NSCLC non-squamous 1st line.
Tecentriq is als monotherapie geïndiceerd voor de behandeling van volwassen patiënten met lokaal gevorderde of gemetastaseerde niet-kleincellige longkanker (NSCLC) na eerdere behandeling met chemotherapie. Patiënten met EGFR-activerende mutaties of ALK-positieve mutaties moeten ook doelgerichte behandeling hebben ontvangen voor ze Tecentriq krijgen.
Avelumab
Brigatinib
Durvalumab
Durvalumab / Tremelimumab
Osimertinib
Pembrolizumab
Rociletinib
Rovalpituzumab tesirine
Veliparib
Lung other
Alpha-1-antitrypsin
Mepolizumab
Lymphoma
Axicabtagene ciloleucel
Brentuximab vedotin
Ibrutinib
Follicular lymphoma (FL), relapsed / refractory.
Mantle cell lymphoma (MCL), 1L.
Marginal zone lymphoma (MZL), relapsed / refractory.
Non-germinal center B-cell-like (non-GCB) diffuse large B-cell lymphoma (DLBCL), 1L.
Obinutuzumab
Tisagenlecleucel
Mesothelioma
Nintedanib
Nivolumab
Metabolic diseases
Asfotase alfa
Burosumab
Cerliponase alfa
Chenodeoxycholzuur
Cholic acid
Cyclodextrine (Hydroxypropyl betadex)
Ibiglustat
Idursulfase-IT
Levamisole (hydrochloride)
Metreleptin
Migalastat
Neod001
Patiromer
Pegvaliase
Sebelipase alfa
Sodium benzoate
Sodium zirconium cyclosilicate
Velmanase alfa
Vestronidase alfa
Volanesorsen (sodium)
Multiple Myeloma
Denosumab
Pembrolizumab
Plitidepsin
Multiple sclerosis
Biotin
Cladribine
Masitinib
Ocrelizumab
Ozanimod
Siponimod
Muscular diseases
Botulinum A toxin
Lower limb spasticity (LLS), in adults post stroke or traumatic brain injury (TBI).
Lower limb spasticity (LLS), post stroke.
Eculizumab
Eteplirsen
Idebenone
Mexiletine HCl
Nusinersen
Valbenazine
Neuroendocrine cancer
Lutetium-177
Telotristat etiprate
Neurological disorders other
Botulinum A toxin
CM-AT / CM-4612
Esketamine
Patisiran
Other chronic immune diseases
Budesonide
Forigerimod (Rigerimod)
Icatibant
Lesinurad / allopurinol
Other hematology
Romiplostim
Ropeginterferon alfa-2b
Ovarian cancer
Niraparib (tosylate monohydrate)
Olaparib
Paclitaxel
Rucaparib
Veliparib
Pancreatic cancer
Olaparib
Parkinson's
Pimavanserin
Prostate cancer
Abiraterone
Olaparib
Padeliporfin
Psychiatry
Brexpiprazole
Cariprazine (hydrochloride)
Esketamine
Lurasidone
Rheumatism
Adalimumab
Sirukumab
Upadacitinib
Skin cancer
Avelumab
Binimetinib
Encorafenib
Nivolumab
Pembrolizumab
Skin diseases
Abatacept
Adalimumab
Baricitinib
Certolizumab pegol
Dupilumab
Guselkumab
Ixekizumab
Nemolizumab
Risankizumab
Tildrakizumab
Tofacitinib
Sleep disorders
Melatonin
Pitolisant
Tasimelteon
Stomach cancer
Atezolizumab
Masitinib
Pembrolizumab
Thrombosis
Caplacizumab
Unknown
Anacetrapib
MABp1
Viral infections other
Bictegravir / emtricitabine / tenofovir alafenamide fumaraat
Darunavir / cobicistat / emtricitabine / tenofovir alafenamide
Dolutegravir /rilpivirine
Emtricitabine / tenofovir disproxil fumarate
Glecaprevir / pibrentasvir
Letermovir
Peramivir
Recombinant zoster vaccin
Sofosbuvir / velpatasvir / voxilaprevir
Naar boven
National Health Care Institute
Login
Understanding of expected market entry
of innovative medicines
Service
Contact
Downloads
Export
About this site
Copyright
Privacy
Cookies
Toegankelijkheid
Kwetsbaarheid melden
Over de Horizonscan
About the Horizon Scan
Nederlands
English